These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12870431)

  • 21. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Experimental study of MAT1 gene silencing mediated by siRNA in pancreatic cancer].
    Liu JP; Yuan SZ; Zhang SN
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2719-23. PubMed ID: 18167254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. siRNA--getting the message out.
    Lee SH; Sinko PJ
    Eur J Pharm Sci; 2006 Apr; 27(5):401-10. PubMed ID: 16442784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small interfering RNA for experimental cancer therapy.
    Tong AW; Zhang YA; Nemunaitis J
    Curr Opin Mol Ther; 2005 Apr; 7(2):114-24. PubMed ID: 15844618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
    Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
    Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
    Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
    Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery.
    Gary DJ; Puri N; Won YY
    J Control Release; 2007 Aug; 121(1-2):64-73. PubMed ID: 17588702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. siRNA for gene silencing: a route to drug target discovery.
    Jones SW; Souza PM; Lindsay MA
    Curr Opin Pharmacol; 2004 Oct; 4(5):522-7. PubMed ID: 15351359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis.
    Schiffelers RM; Xu J; Storm G; Woodle MC; Scaria PV
    Arthritis Rheum; 2005 Apr; 52(4):1314-8. PubMed ID: 15818667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breaking down the barriers: siRNA delivery and endosome escape.
    Dominska M; Dykxhoorn DM
    J Cell Sci; 2010 Apr; 123(Pt 8):1183-9. PubMed ID: 20356929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA interference (RNAi) in hematology.
    Scherr M; Steinmann D; Eder M
    Ann Hematol; 2004 Jan; 83(1):1-8. PubMed ID: 14574462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model.
    Podesta JE; Al-Jamal KT; Herrero MA; Tian B; Ali-Boucetta H; Hegde V; Bianco A; Prato M; Kostarelos K
    Small; 2009 May; 5(10):1176-85. PubMed ID: 19306454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma.
    Guo B; Zhang Y; Luo G; Li L; Zhang J
    Anat Rec (Hoboken); 2009 May; 292(5):633-9. PubMed ID: 19382240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems.
    Reischl D; Zimmer A
    Nanomedicine; 2009 Mar; 5(1):8-20. PubMed ID: 18640078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo.
    Kang CS; Zhang ZY; Jia ZF; Wang GX; Qiu MZ; Zhou HX; Yu SZ; Chang J; Jiang H; Pu PY
    Cancer Gene Ther; 2006 May; 13(5):530-8. PubMed ID: 16410821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.
    Sun Y; Li Z; Li L; Li J; Liu X; Li W
    Int J Mol Med; 2007 Apr; 19(4):705-11. PubMed ID: 17334648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
    Takahashi Y; Nishikawa M; Takakura Y
    Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Toll-like receptors in antisense and siRNA [corrected].
    Agrawal S; Kandimalla ER
    Nat Biotechnol; 2004 Dec; 22(12):1533-7. PubMed ID: 15583662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted quantum dot conjugates for siRNA delivery.
    Derfus AM; Chen AA; Min DH; Ruoslahti E; Bhatia SN
    Bioconjug Chem; 2007; 18(5):1391-6. PubMed ID: 17630789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.